Value proposition

BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.

The Company’s flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury (AKI), a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, clinicians can identify patients potentially at risk of AKI more rapidly than is possible with the current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide.

BioPorto has facilities in Copenhagen, Denmark, and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit www.bioporto.com.

To learn more about our products and their availability in your country, please visit https://bioporto.com/products/.

Posts are not intended for a U.S. audience. If you are from the United States, you are encouraged to visit https://www.linkedin.com/company/bioporto-diagnostics-inc-us/

Social Media Community Guidelines: https://bioporto.com/social-media/

Antibodies, Acute kidney injury (AKI) biomarker, In-vitro Diagnostics (IVD), Assay Development, Complement and Innate Immunity, Appetite Regulating Hormones, NGAL biomarker, diagnostics, generic Rapid Assay Device (gRAD), Lateral flow assay development (gRAD), Clinical research, drug induced kidney injury (DIKI), FDA Qualified Biomarker (BQP), scientific and pre-clinical drug research, pre-clinical, non-clinical research, clinical research, NGAL ELISA kits (human and animal, and research & development